CY009

CY009 is a pegylated protein therapeutic being developed by Letolab for the treatment of inflammatory and immunological diseases. It is designed to modulate the interleukin-2 (IL-2) receptor pathway, which plays a critical role in regulating immune responses. Pegylation is employed to enhance the protein's stability and extend its circulating half-life, potentially improving its pharmacokinetic profile and allowing for less frequent administration. While the specific functional role (agonist or antagonist) is not explicitly detailed in the company's pipeline, IL-2 receptor modulation in immunology typically aims to restore immune balance, either by stimulating regulatory T cells or inhibiting effector T cell activity. As of early 2024, CY009 is in the development candidate stage, representing a preclinical phase of drug development.